Sino-Biocan Completes Nearly Hundred Million RMB in Series B Financing to Provide High-Quality Fully Automatic Cell Preparation Systems for the Global Market

Sino-Biocan (Shanghai) Biotech Ltd. recently completed nearly a hundred million RMB in Series B financing. The raised funds will be primarily used to establish a modern production system, enhance overall research and development capabilities, and obtain global registration certification, aiming to rapidly expand into key global markets.

It is noteworthy that Sino-Biocan is not only a developer and manufacturer of equipment but also a technical service expert providing innovative comprehensive solutions. With the capability to produce consumables and liquid products at a GMP level, along with corresponding registration capabilities from authoritative institutions, Sino-Biocan can offer a one-stop comprehensive solution covering equipment, consumables, and liquid reagent products. This facilitates providing excellent closed-cell preparation tool solutions for innovative biopharmaceutical companies, supporting the high-quality development of cellular and gene therapy in China.

Implementation of Orders in Southeast Asia and Eastern Europe Advances Internationalization Strategy

Sino-Biocan's international market layout is equally impressive. In 2023, the company embarked on its inaugural year of global expansion, actively establishing a presence overseas and securing orders in Southeast Asia and Eastern Europe, thus laying the groundwork for realizing its globalization strategy.

In 2024, Sino-Biocan's pace in global strategy has significantly accelerated. In January, the company made noteworthy progress in Russia, with further strategic plans to establish a Sino-Biocan strategic cooperation and training center at the Raisa Gorbacheva Children's Hematology and Transplantation Research Institute and the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, providing local customers with cell therapy research and professional training.

Additionally, Sino-Biocan is actively expanding into markets in North America, South America, Western Europe, and Central Asia, engaging in broad and diversified cooperation with local partners to drive the internationalization of the company's operations.

Upholding Original Breakthroughs to Develop Wukong Series Integrated Machines for Cell Preparation, Achieving Single-Platform Production of Multiple Cell Series, including CAR-T

The transition from manual to automated, closed production system processes has become a consensus in cell preparation for CAR-T pharmaceutical enterprises. The use of fully enclosed automated tools is a necessary path for the development of the CGT industry.

Based on this premise, Sino-Biocan introduced the Wukong series cell preparation integrated machine. This device fully completes the entire process of CAR-T cell preparation, including key steps such as cell separation, selection, genetic modification, cultivation, formulation, and packaging. Its broad applications include IIT clinical research, FASTCAR process cell therapy technology, multicenter clinical trials, and future high-speed markets at hospitals, adapting to a wide range of cell preparation scenarios.

The introduction of the Wukong series integrated machines has not only greatly increased production efficiency and reduced research and development costs and the operational expenses of cleanrooms but also provided precise and reproducible GMP-grade cell preparation. This ensures the stability and uniformity of cell quality, bringing significant economic benefits and product quality assurance to biopharmaceutical companies, driving industry technological advancements and upgrades.

Joint Support from New and Existing Shareholders to Build a Leading Domestic Head in CGT Tools

From a small team to a current staff of hundreds, from initially benchmarking imported products to now leading in the industry with pioneering products, from China to the world... Sino-Biocan strides forward in the upstream CGT sector, continuously bringing innovative solutions to the industry and empowering sustainable development in the CGT sector.

In response to the latest round of financing, Wei Dongbing, the founder of Sino-Biocan, stated, "Sino-Biocan will continue to leverage its outstanding closed-cell preparation tool solutions and its global business network to provide high-quality services to global biopharmaceutical companies, driving the global development of cellular and gene therapy. In the future, Sino-Biocan will steadfastly uphold an innovative spirit, bringing more innovative solutions to the field of cell and gene therapy tools, to realize its strategic goal of globalization."